Published in J Gen Virol on October 01, 1971
Many rhinovirus serotypes share the same cellular receptor. J Virol (1984) 3.59
Identification and characterization of the virus causing rabbit hemorrhagic disease. J Virol (1990) 1.64
Use of guinea pig embryo cell cultures for isolation and propagation of group A coxsackieviruses. J Clin Microbiol (1981) 1.12
Properties and origins of infectious rhinovirus type 14 particles of different buoyant densities. J Virol (1975) 1.03
Ion channels in southern bean mosaic virus capsid. Biophys J (1987) 0.88
Ion channels in icosahedral virus: a comparative analysis of the structures and binding sites at their fivefold axes. Biophys J (1992) 0.83
Receptors for Theiler's murine encephalomyelitis virus: characterization by using rabbit antiviral antiserum. J Virol (1988) 0.77
Enterovirus type 70 virion and intracellular proteins. J Virol (1976) 0.76
A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain (1988) 18.17
The three-dimensional structure of foot-and-mouth disease virus at 2.9 A resolution. Nature (1989) 5.87
Classification of rhabdovirus proteins: a proposal. J Virol (1972) 5.54
Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature (1982) 5.50
Myristylation of picornavirus capsid protein VP4 and its structural significance. Nature (1987) 5.26
Unique features of internal initiation of hepatitis C virus RNA translation. EMBO J (1995) 4.44
The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid). J Gen Virol (1989) 3.53
The proteins of biologically active sub-units of vesicular stomatitis virus. J Gen Virol (1970) 3.44
Propranolol as ocular hypotensive agent. Br J Ophthalmol (1967) 3.42
Multi-disciplinary clinical study of Smith-Magenis syndrome (deletion 17p11.2) Am J Med Genet (1996) 3.17
The complete nucleotide sequence of the RNA coding for the primary translation product of foot and mouth disease virus. Nucleic Acids Res (1984) 3.00
An infectious molecular clone of a Japanese genotype 1b hepatitis C virus. Hepatology (1999) 3.00
Human pharmacokinetic and pharmacodynamic studies on the atenolo (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug. Br J Clin Pharmacol (1976) 2.99
Dissection of vesicular stomatitis virus into the infective ribonucleoprotein and immunizing components. J Gen Virol (1970) 2.85
Serological relationships between different strains of vesicular stomatis virus. J Gen Virol (1972) 2.68
Kinetic tuning of myosin via a flexible loop adjacent to the nucleotide binding pocket. J Biol Chem (1998) 2.62
Assignment of the genome segments of bluetongue virus type 1 to the proteins which they encode. Virology (1984) 2.60
The ribonucleic acids of the infective and interfering components of vesicular stomatitis virus. J Gen Virol (1967) 2.57
Chemical basis of antigenic variation in foot-and-mouth disease virus. Nature (1984) 2.52
Genetically engineered foot-and-mouth disease viruses with poly(C) tracts of two nucleotides are virulent in mice. J Virol (1993) 2.50
Internal initiation of translation of hepatitis C virus RNA: the ribosome entry site is at the authentic initiation codon. RNA (1996) 2.45
3'-Terminal nucleotide sequences in the genome RNA of picornaviruses. Nature (1978) 2.40
Protein covalently linked to foot-and-mouth disease virus RNA. Nature (1977) 2.35
Location of the initiation site for protein synthesis on foot-and-mouth disease virus RNA by in vitro translation of defined fragments of the RNA. J Virol (1980) 2.34
All foot and mouth disease virus serotypes initiate protein synthesis at two separate AUGs. Nucleic Acids Res (1987) 2.22
Characterisation of a rotavirus.20b. Nature (1975) 2.21
A physico-chemical sub-grouping of the mammalian picornaviruses. J Gen Virol (1973) 2.08
A re-appraisal of the biochemical map of foot-and-mouth disease virus RNA. J Gen Virol (1978) 2.06
The replication of picornaviruses. J Gen Virol (1979) 2.03
Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature (1987) 2.00
Poly(C) in animal viral RNAs. Nature (1974) 1.95
Sequence and location of the poly C tract in aphtho- and cardiovirus RNA. Nucleic Acids Res (1979) 1.95
Model for vesicular stomatitis virus. J Virol (1972) 1.92
Infective virus substructure from vesicular stomatitis virus. J Virol (1967) 1.89
The antigens of vesicular stomatitis virus. I. Separation and immunogenicity of three complement-fixing components. J Immunol (1966) 1.89
Structural and serological evidence for a novel mechanism of antigenic variation in foot-and-mouth disease virus. Nature (1990) 1.86
Surface structure of vesicular stomatitis virus. J Gen Virol (1969) 1.82
The nucleotide sequence of cDNA coding for the structural proteins of foot-and-mouth disease virus. Gene (1982) 1.82
Further physicochemical characterization of Nodamura virus. Evidence that the divided genome occurs in a single component. J Gen Virol (1978) 1.78
A foot and mouth disease syndrome in pigs caused by an enterovirus. Nature (1968) 1.74
Molecular cloning of foot and mouth disease virus genome and nucleotide sequences in the structural protein genes. Nature (1981) 1.73
Antibody-complexed foot-and-mouth disease virus, but not poliovirus, can infect normally insusceptible cells via the Fc receptor. Virology (1993) 1.72
Diazoxide in treatment of primary pulmonary hypertension. Br Heart J (1978) 1.71
More precise location of the polycytidylic acid tract in foot and mouth disease virus RNA. J Virol (1978) 1.69
Presence of a covalently linked protein on calicivirus RNA. J Gen Virol (1978) 1.66
Comparison of the amino acid sequence of the major immunogen from three serotypes of foot and mouth disease virus. Nucleic Acids Res (1982) 1.66
Antigenic differences between isolates of swine vesicular disease virus and their relationship to Coxsackie B5 virus. Nature (1973) 1.63
Potential secondary and tertiary structure in the genomic RNA of foot and mouth disease virus. Nucleic Acids Res (1987) 1.62
Differentiation of convalescent animals from those vaccinated against foot-and-mouth disease by a peptide ELISA. Vaccine (1999) 1.61
Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants. Nature (1987) 1.57
The location of the ploy(C) tract in the RNA of foot-and-mouth disease virus. J Gen Virol (1976) 1.52
Biochemical analysis of a virulent and an avirulent strain of foot-and-mouth disease virus. J Gen Virol (1977) 1.52
Heterogeneity of the genome-linked protein of foot-and-mouth disease virus. J Virol (1980) 1.50
Purification and identification of the RNA-dependent RNA polymerase of foot-and-mouth disease virus. J Gen Virol (1979) 1.50
Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother (2000) 1.50
Induction of T-helper cell response to hepatitis B core antigen in chronic hepatitis B: a major factor in activation of the host immune response to the hepatitis B virus. Hepatology (1995) 1.50
Beta-sympathetic blockade in hyperthyroidism. Lancet (1966) 1.49
Sequences of vesicular stomatitis virus RNA in the region coding for leader RNA, N protein mRNA, and their junction. Proc Natl Acad Sci U S A (1979) 1.48
Transient expression of cellular polypyrimidine-tract binding protein stimulates cap-independent translation directed by both picornaviral and flaviviral internal ribosome entry sites In vivo. Mol Cell Biol (2000) 1.47
Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration (1995) 1.45
Haemodynamic changes during methohexitone anaesthesia in patients with supraventricular arrhythmias. Br J Anaesth (1967) 1.45
Formaldehyde as an inactivant. Vaccine (1995) 1.42
Comparison of azabicyclic esters and oxadiazoles as ligands for the muscarinic receptor. J Med Chem (1991) 1.42
Mental health concerns of Canadian adolescents: a consumer's perspective. Can J Psychiatry (1996) 1.41
"Instant-mix" whole brain photon with neutron boost radiotherapy for malignant gliomas. Int J Radiat Oncol Biol Phys (1990) 1.40
Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther (1998) 1.40
Sleep habits and patterns of college students: a preliminary study. J Am Coll Health (2001) 1.40
Biochemical identification of viruses causing the 1981 outbreaks of foot and mouth disease in the UK. Nature (1981) 1.39
The antigens of vesicular stomatitis virus. II. The presence of two low molecular weight immunogens in virus suspensions. J Immunol (1966) 1.38
Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPR. Br J Pharmacol (1999) 1.38
Picornaviridae. Intervirology (1974) 1.36
Two initiation sites for foot-and-mouth disease virus polyprotein in vivo. J Gen Virol (1985) 1.35
Effects of posterior fossa decompression with and without duraplasty on Chiari malformation-associated hydromyelia. Neurosurgery (2000) 1.35
Autogenous vein grafting in femoropopliteal atherosclerosis: the limits of its effectiveness. Surgery (1979) 1.34
The sequence of foot-and-mouth disease virus RNA to the 5' side of the poly(C) tract. Gene (1985) 1.31
A comparative chemical and serological study of the full and empty particles of foot-and mouth disease virus. J Gen Virol (1975) 1.27
Host cell selection of antigenic variants of foot-and-mouth disease virus. J Gen Virol (1989) 1.26